Mod GRF (1–29)

CJC-1295 without DAC; [D-Ala², Gln⁸, Ala¹⁵, Leu²⁷]-GRF(1–29)-NH₂; tetrasubstituted GRF(1–29)

Identity

Sequence

Y-(D-A)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2

Three-letter

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Length

29 residues

Modifications

D-Ala²; Gln⁸; Ala¹⁵; Leu²⁷; C-terminal amide

Formula

C152H252N44O42

Average mass

3367.9 Da

CAS

863288-34-0

Specifications (per released lot)

Purity

≥ 98 % by RP-HPLC, 220 nm

Identity

ESI-MS; observed mass within 0.1 % of calculated

Form

White to off-white lyophilized powder

Counter-ion

Trifluoroacetate; acetate on request

Net peptide content

Reported per lot (typically 70–90 % of gross mass; the balance is counter-ion and water)

Vial sizes

5 mg · 10 mg · 25 mg net peptide; bulk on quotation

Storage

−20 °C, desiccated, protected from light. Ships at ambient temperature.

Documents

Lot certificate of analysis (COA library); safety data sheet in WHMIS 2015 format, enclosed with every shipment

Research context

Stabilized analogue of GHRH(1–29)-NH₂ carrying four substitutions that resist dipeptidyl-peptidase IV cleavage and asparagine deamidation. Used as a GHRH-receptor agonist in in-vitro and animal studies. Not the drug-affinity-complex (DAC) form.

Literature context is provided to help laboratories identify the reagent. It is not a claim about effects in people and does not describe any use outside in-vitro or approved animal research.